Royalty Pharma plc (RPRX) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $4.38B; Treasury Stock, Common, ValueUSD $2.72M; Treasury Stock, ValueUSD (m); Retained Earnings (Accumulated Deficit)USD $2.46B.
- 2026-03-31: Additional Paid in CapitalUSD $4.38B; Treasury Stock, Common, ValueUSD $2.71M; Treasury Stock, ValueUSD (m); Retained Earnings (Accumulated Deficit)USD $2.51B.
- 2025-12-31: Additional Paid in CapitalUSD $4.12B; Treasury Stock, Common, ValueUSD $2.61M; Treasury Stock, ValueUSD (m); Retained Earnings (Accumulated Deficit)USD $2.36B.
- 2025-09-30: Additional Paid in CapitalUSD $4.11B; Treasury Stock, Common, ValueUSD $2.61M; Treasury Stock, ValueUSD (m); Retained Earnings (Accumulated Deficit)USD $2.30B.
Royalty Pharma plc Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Treasury Stock, Value USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Treasury Stock, Value, Acquired, Cost Method USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.38B | $2.72M | (m) | $2.46B | $9.79B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $4.38B | $2.71M | (m) | $2.51B | $9.94B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $4.12B | $2.61M | (m) | $2.36B | $9.71B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $4.11B | $2.61M | (m) | $2.30B | $9.62B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $4.13B | $2.61M | (m) | $2.22B | $9.49B | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $4.21B | $2.65M | (m) | $2.48B | $9.78B | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $4.10B | $2.66M | $2.66M | $2.85B | $10.34B | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $4.11B | (m) | $2.66M | $2.76B | $10.26B | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $4.10B | (m) | $2.66M | $2.38B | $9.75B | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $4.07B | (m) | $2.65M | $2.43B | $9.86B | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $4.01B | (m) | $2.63M | $2.52B | $10.08B | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $4.01B | (m) | $2.62M | $2.13B | $9.59B | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $4.03B | (m) | $2.63M | $2.25B | $9.81B | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $3.74B | (m) | $2.83M | $2.22B | $9.82B | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $3.67B | (m) | $2.81M | $1.96B | $9.53B | $0.00 | (m) | (m) | (m) | (m) |
| 2022-09-30 | $3.63B | (m) | $2.79M | $2.50B | $10.42B | $16.90M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $3.57B | (m) | $2.75M | $2.45B | $10.41B | $13.18M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $3.54B | (m) | $2.74M | $2.22B | $10.14B | $12.30M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $3.51B | (m) | $2.71M | $2.26B | $10.25B | $16.49M | (m) | (m) | (m) | 12 month · $28.48M |
| 2021-09-30 | $3.45B | (m) | $2.69M | $2.32B | $10.39B | $20.55M | (m) | (m) | (m) | (m) |
| 2021-06-30 | $3.42B | (m) | $2.66M | $2.29B | $10.41B | $28.67M | (m) | (m) | (m) | (m) |
| 2021-03-31 | $2.93B | (m) | $2.36M | $1.92B | $9.84B | $29.45M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $2.87B | (m) | $2.32M | $1.92B | $9.90B | $34.40M | (m) | (m) | (m) | 12 month · $6.86M |
| 2020-09-30 | $2.61B | (m) | $2.15M | $1.81B | $9.80B | $34.75M | (m) | 3 month · $858.00K | (m) | (m) |
| 2020-06-30 | $2.56B | (m) | $2.12M | $1.57B | $9.39B | $30.52M | (m) | (m) | 3 month · $3.74M 6 month · $3.74M | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $7.16B | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | (m) | $4.27M | $2.83B | $6.14B | $2.09M | 12 month · $4.27M | (m) | (m) | 12 month · $6.19M |
| 2019-09-30 | (m) | (m) | (m) | (m) | $4.90B | (m) | 9 month · $4.23M | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | $4.65B | (m) | 3 month · $1.90M 6 month · $4.23M | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | $4.71B | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $4.55B | (m) | (m) | (m) | (m) | 12 month · $8.00M |
| 2017-12-31 | (m) | (m) | (m) | (m) | $4.46B | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |